Drug Profile
Research programme: NLRP3 inflammasome inhibitors - Nodthera
Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Selvita
- Developer Nodthera
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Inflammasome inhibitors; NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for research development in Inflammation in United Kingdom
- 18 Aug 2021 Early research is ongoing the United Kingdom (Nodthera pipeline, August 2021)
- 13 Jul 2021 Nodthera files for patent protection with Patent Cooperation Treaty (PCT) for Selective inhibitors of NLRP3 inflammasome Worldwide